Business Wire

AURAK

15.12.2018 11:51:08 CET | Business Wire | Press release

Share
AURAK Gains SACSCOC Accreditation

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/

SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now joins the very small group of elite international higher education institutions that have attained SACSCOC accreditation and can enjoy the diverse benefits of membership in this highly revered organization.

“Accreditation by SACSCOC signifies that the institution has a mission appropriate to higher education, has resources, programs, and services sufficient to accomplish and sustain that mission, and maintains clearly specified educational objectives that are consistent with its mission and appropriate to the degrees its offers, and that indicate whether it is successful in achieving its stated objectives.”

“The culmination of the accreditation process is a public statement of an institution’s continuing capacity to provide effective programs and services based on agreed-upon requirements. The statement of an institution’s accreditation status with SACSCOC also represents an affirmation of an institution’s continuing commitment to the Commission’s principles and philosophy of accreditation.”

AURAK is a nonprofit, government-owned institution of higher education which provides the local, regional and international communities with a North American-style education integrated with Arabic customs and traditions. It is licensed by the Ministry of Education in the UAE and offers a total of 22 accredited undergraduate and graduate programs across a wide range of disciplines. Despite having this primary local accreditation, AURAK was determined to broaden its impact in higher education by obtaining internationally recognized institutional and program accreditations. To date, the institution has six programs accredited by the Accreditation Board for Engineering and Technology (ABET) and institutional accreditation by SACSCOC. It should be noted that in the case of institutional accreditation by SACSCOC, an institution is also expected to document and demonstrate the quality and effectiveness of all its programs and services although the agency does not award individual program accreditation.

AURAK has been working diligently towards obtaining SACSCOC accreditation since 2014 and successfully achieved candidacy status in July of 2017. This paved the way for the institution to undergo even more rigorous and comprehensive onsite review by a SACSCOC Accreditation Committee. The Committee found the institution to be in compliance with all accreditation standards and requirements. Further internal reviews were conducted by SACSCOC in keeping with its multi-tiered peer review process, the culmination of which was AURAK obtaining SACSCOC accreditation.

This was a formidable achievement that was four years in the making. It demonstrates the tenacity, determination and commitment of AURAK to achieving excellence in all its undertakings – for its students, faculty, staff and other stakeholders.

“The long- standing dream and goal has come true in a record time. The report is positive and clear.” Professor Hassan beamed proudly during the declaration of AURAK’s SACSCOC accreditation status. “Today AURAK is among the first universities in the Middle East and North Africa (MENA) region to successfully initiate and complete the entire accreditation process as an applicant institution to secure membership from the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), affirming that AURAK is not only as an institution of quality among Arabic educational institutions, but also on an international level as well. This accreditation validates our claims of providing students with a highly rigorous curriculum from the credentialed and highly knowledgeable faculty we have always strived to hire and support. AURAK has achieved in a very short time what some other institutions have failed to do in decades.

I would like to seize this opportunity to thank the AURAK family and supporters for their loyalty, dedication, and hard work. Without them, AURAK would not be the exemplar of educational excellence it is. Today our aspirations and our hard work have been realized. In gaining SACSCOC membership we join a community of highly respected institutions. We look forward to offering a vast array of educational opportunities through which we will continue to develop and excel.”

*Source: AETOSWire

Contact:

American University of Ras Al Khaimah Helen Amhani , Manager, Department of Communications and Public Relations +97172210900 Ext: 1445 hamhani@aurak.ac.ae

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye